

## Special Issue

# The Role of Ceramide Synthases in Cancers

### Message from the Guest Editor

Ceramide synthases (CerS) are essential enzymes of the sphingolipid pathway involved in sphingolipid de novo synthesis, as well as in the salvage pathway. Although several publications about CerS in cancer development or cancer treatment have already been published, there are still many unanswered questions. This upcoming Special Issue will bring together the current state of knowledge in the field of CerS and ceramides in cancer formation. Original work and reviews that focus on CerS and ceramides of distinct chain length in cancer development or cancer treatment are welcome and will be combined in this Special Issue to give the reader a comprehensive overview of the most recent findings concerning this topic with its many facets.

---

### Guest Editor

Prof. Dr. Sabine Groesch

Faculty of Medicine, Institute of Clinical Pharmacology, Goethe-University Frankfurt, 60590 Frankfurt, Germany

---

### Deadline for manuscript submissions

closed (31 March 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/33099](https://mdpi.com/si/33099)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)